PEAK6
NTLA icon

PEAK6’s Intellia Therapeutics NTLA Stock Holding History

PEAK6’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-346,700
Closed -$3.12M – 3108
2025
Q4 		$3.12M Buy
346,700
+2,800
+0.8% +$38.5K 0.01% 1189
2025
Q3 		$5.94M Buy
343,900
+189,500
+123% +$2.33M 0.01% 934
2025
Q2 		$1.45M Buy
154,400
+43,500
+39% +$357K ﹤0.01% 1609
2025
Q1 		$788K Buy
110,900
+36,100
+48% +$365K ﹤0.01% 1878
2024
Q4 		$872K Buy
+74,800
New +$1.17M ﹤0.01% 1880

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PEAK6's NTLA Position: Q1 2026 in Review

PEAK6 sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 374 shares — an estimated $3.36K sold.

PEAK6 first reported a position in NTLA in Q4 2024 and held it in 4 quarters. The position peaked at $358K in Q4 2024. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • PEAK6 reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • PEAK6 sold 374 Intellia Therapeutics shares in Q1 2026, an estimated $3.36K.
  • PEAK6 first reported a position in Intellia Therapeutics in Q4 2024 and held it in 4 quarters.
  • PEAK6's Intellia Therapeutics position peaked at $358K in Q4 2024.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on PEAK6's 13F filing for Q1 2026, filed 14 May 2026.